A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Clinical Cancer Research|2019Cited by 52
Figure S3 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Manuel D. Gahete et al.|Unknown|2023Cited by 0
Supplementary Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0
Data from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0
Figure S2 from A Somatostatin Receptor Subtype-3 (SST<sub>3</sub>) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Vandana Gupta et al.|Unknown|2023Cited by 0